Wall Street Zen Upgrades Glaukos (NYSE:GKOS) to “Buy”

Posted by George Bondi on Aug 3rd, 2026

Glaukos (NYSE:GKOS – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other brokerages have also commented on GKOS. Wells Fargo & Company lifted their target price on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group began coverage on Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target on the stock. Truist Financial raised their price objective on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday. BTIG Research lifted their price objective on shares of Glaukos from $164.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Citigroup boosted their target price on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $177.33.

Check Out Our Latest Stock Report on GKOS

Glaukos Stock Down 0.1%

NYSE:GKOS opened at $166.52 on Friday. The company has a market capitalization of $9.82 billion, a price-to-earnings ratio of -51.24 and a beta of 0.78. Glaukos has a one year low of $73.16 and a one year high of $184.00. The stock has a 50-day simple moving average of $138.11 and a 200 day simple moving average of $125.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04.

Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. Glaukos’s revenue for the quarter was up 49.6% compared to the same quarter last year. Sell-side analysts predict that Glaukos will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The stock was sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the completion of the transaction, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. The trade was a 18.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This represents a 12.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 40,000 shares of company stock worth $6,028,800 over the last quarter. Insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of hedge funds have recently added to or reduced their stakes in GKOS. AQR Capital Management LLC grew its position in shares of Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after acquiring an additional 198 shares during the last quarter. Jones Financial Companies Lllp lifted its position in Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the period. M&T Bank Corp acquired a new position in Glaukos during the 2nd quarter valued at about $203,000. Finally, Gamco Investors INC. ET AL boosted its stake in Glaukos by 10.7% during the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock valued at $826,000 after purchasing an additional 773 shares during the period. 99.04% of the stock is currently owned by institutional investors.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

Positive Sentiment: Quarterly results exceeded expectations. Glaukos reported second-quarter revenue of $185.6 million, up 49.6% year over year and well above the $150.9 million consensus estimate. Its adjusted loss of $0.14 per share was narrower than the expected $0.21 loss, supported by growth in iDose TR and Epioxa. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth
Positive Sentiment: Management raised its 2026 outlook. Glaukos now expects net sales of $680 million to $700 million, with iDose TR revenue projected at $275 million to $280 million. The higher forecast signals continued commercial momentum and was a key reason the stock advanced. Glaukos outlines 2026 sales outlook
Positive Sentiment: Clinical and analyst catalysts added support. The company reported progress on its PRESERFLO study, while BTIG raised its price target from $164 to $193 and maintained a Buy rating. BTIG raises Glaukos price target
Neutral Sentiment: UBS Group initiated coverage of Glaukos, potentially broadening institutional attention, although the available report does not provide a detailed rating or price target. UBS initiates Glaukos coverage
Negative Sentiment: Valuation and profitability remain risks. Despite the improved results, Glaukos remains unprofitable, and commentary questioned whether the stock’s strong rally has priced in much of its growth potential. Future gains may depend on continued iDose TR adoption and execution against the raised forecast. Glaukos record sales and valuation analysis

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.